Labsmith and Fluigent Join Forces
News Jan 23, 2013
Fluigent, headquartered in Paris, France, is a microfluidic flow control and fluid handling expert. LabSmith Inc., based in Livermore, California, offers a wide range of tools for innovative laboratory electronic and microfluidic solutions.
LabSmith and Fluigent join forces in the promotion of a microfluidic voltage control platform composed of LabSmith’s HVS448 Eight Channel High Voltage Sequencer and Fluigent’s MFCSTM (Microfluidic Flow Control System) and Electrowell device. Promotion of this tool combination highlights a simplified automated platform for the control of fluids and voltage in a microfluidic set-up.
“Combining the HVS448, MFCSTM and Electrowell systems will provide customers with a combined microfluidic solution for precise fluid and voltage control,” explains Fluigent CEO Franҫois Leblanc. LabSmith President and CEO, Kirsten Pace, agrees, stating, “The approach promoted by LabSmith and Fluigent will be useful for many lab-on-a-chip electrokinetic and electrophoretic applications in R&D laboratories.”
Fluigent and LabSmith plan to leverage their technical expertise and market experience to offer products that can be easily integrated into any microfluidics experiments for R&D laboratories and industrial applications.
Microanalysis of Biological Samples for Early Disease DetectionNews
A group of researchers from Osaka University has now developed a nonlinear optical crystal (NLOC) chip, which combines THz waves with a microfluidic device, utilizing the close proximity of the THz wave source and the solution of interest in a microchannel.READ MORE
Novel Green Chemistry Method Improves Pharmaceutical Manufacturing EfficiencyNews
About 70 percent of pharmaceuticals are manufactured using palladium-driven catalytic processes that are either fast or efficient - but not both. Researchers have now developed a green chemistry method that combines aspects of both processes to improve efficiency at a minimal cost of processing time.READ MORE
Radioprotective Drugs Assessed Using Human Gut Organ-on-a-ChipNews
Researchers have published a study using an organ-on-a-chip (Organ Chip) model of the human gut that reveals the intestinal blood vessel cells may play an important part in radiation-induced intestinal injury, and it confirms that a potential radioprotective drug, dimethyloxaloylglycine (DMOG), suppresses the intestine’s responses to radiation injury.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018